Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.
Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, ...
Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a ...
A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ...
The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a ...
The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a ...
Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure ...
The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, ...
A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ...
The fundraise is the firm’s largest to date, providing a lift for a European biotech industry that’s fallen further behind ...
The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent ...
Cerevance plans to meet with the FDA to determine next steps for a new kind of medicine known as solengepras, now that it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results